Difference between revisions of "Plinabulin (NPI-2358)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "Category:Oral chemotherapy" to "Category:Oral medications") |
Warner-admin (talk | contribs) m (Text replacement - "Category:Drug index" to "Category:Drugs") |
||
| Line 7: | Line 7: | ||
# '''Abstract:''' Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) [http://meetinglibrary.asco.org/content/178367-194 link to abstract] | # '''Abstract:''' Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) [http://meetinglibrary.asco.org/content/178367-194 link to abstract] | ||
| − | [[Category: | + | [[Category:Drugs]] |
[[Category:Chemotherapy]] | [[Category:Chemotherapy]] | ||
[[Category:Oral medications]] | [[Category:Oral medications]] | ||
Revision as of 23:02, 13 June 2018
Mechanism of action
From the NCI Drug Dictionary: An orally active diketopiperazine derivative with potential antineoplastic activity. Plinabulin selectively binds to the colchicine-binding site of tubulin, thereby interrupting equilibrium of microtubule dynamics; mitotic spindle assembly is disrupted, resulting in cell cycle arrest at the M phase and blockage of cell division in tumor cells. In addition, this agent induces tubulin depolymerization in vascular endothelial cells, resulting in the disruption of tumor blood vessel architecture and a selective collapse of tumor vasculature.
Preliminary data
Non-small cell lung cancer
- Abstract: Ramon W. Mohanlal, Ken LLoyd, Lan Huang, Lyudmila Bazhenova. Plinabulin as a novel small molecule clinical stage immuno-oncology agent for NSCLC. J Clin Oncol 35, 2017 (suppl 7S; abstract 139) link to abstract